What You Were Buying Last Week: Rio Tinto
Investors see an opportunity in the depressed price of mining giant Rio Tinto.
What You Were Selling Last Week: Marks & Spencer Group
A price spike sees Marks & Spencer Group take the No. 2 spot in our Top 10 Sells.
What You Were Selling Last Week: J Sainsbury
Shareholders of J Sainsbury sell on a two-year high.
What You Were Selling Last Week: Aviva
Dividend slashing Aviva took the No. 6 spot.
AstraZeneca Unveils New Strategy for Return to Growth
Pharmaceutical giant AstraZeneca aims for "scientific leadership."
Good First-Half Progress at Smiths Group
Smiths Group rewards shareholders with an increased dividend.
BP Fights "Fictitious" Compensation Claims
BP hopes to stem the rising tide of compensation payments.
What You Were Buying Last Week: Lloyds
Investors see an opportunity in a price drop at Lloyds.
What You Were Selling Last Week: Vodafone Group
Telecom giant Vodafone Group topped the sell-off list.
Witan Investment Trust Boosts Dividend for 38th Year in a Row
Witan Investment Trust beats the FTSE 100 over the past five years.
What You Were Selling Last Week: Royal Dutch Shell
Oil supermajor Royal Dutch Shell was in number eight spot.
What You Were Buying Last Week: Royal Bank of Scotland
Investors see an opportunity in beleaguered Royal Bank of Scotland.
Aggreko Powers Ahead on Excellent Results
After a difficult December, Aggreko gives its shareholders some good news.
IMI Delivers Resilient Results
IMI raises its dividend and remain confident for the future.
What You Were Selling Last Week: GlaxoSmithKline
GlaxoSmithKline plc (LON:GSK) took the No. 4 spot.
What You Were Selling Last Week: BP
BP took the No. 7 spot as its oil spill woes continue.
What You Were Buying Last Week: Kazakhmys
Investors see an opportunity in the plunging price of copper miner Kazakhmys.
Serco Group Surges on Excellent Results
Record contract wins leave Serco Group confident for the future.
Pace Reports 50% Increase in Profits
Full-year results from Pace are full of good news.
AstraZeneca Steady After Patent Setback
AstraZeneca plc (LON:AZN) hit down under by court decision.